Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
At close: Apr 22, 5:00 PM EST
Disc Medicine Inc Analyst Ratings
IRONNASDAQ
Disc Medicine Analyst Ratings and Price Targets | NASDAQ:IRON | Benzinga
Disc Medicine Inc has a consensus price target of $93.88 based on the ratings of 17 analysts. The high is $125 issued by Cantor Fitzgerald on February 17, 2026. The low is $43 issued by Raymond James on May 10, 2024. The 3 most-recent analyst ratings were released by Wells Fargo, Truist Securities, and Stifel on March 2, 2026, February 27, 2026, and February 17, 2026, respectively. With an average price target of $90.67 between Wells Fargo, Truist Securities, and Stifel, there's an implied 30.46% upside for Disc Medicine Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Truist Securities
Stifel
Cantor Fitzgerald
BMO Capital
1calculated from analyst ratings
Analyst Ratings for Disc Medicine
Loading calendar...
FAQ
What is the target price for Disc Medicine (IRON) stock?
The latest price target for Disc Medicine (NASDAQ:IRON) was reported by Wells Fargo on March 2, 2026. The analyst firm set a price target for $79.00 expecting IRON to rise to within 12 months (a possible 13.67% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Disc Medicine (IRON)?
The latest analyst rating for Disc Medicine (NASDAQ:IRON) was provided by Wells Fargo, and Disc Medicine maintained their overweight rating.
When was the last upgrade for Disc Medicine (IRON)?
The last upgrade for Disc Medicine Inc happened on June 12, 2023 when Raymond James raised their price target to $75. Raymond James previously had an outperform for Disc Medicine Inc.
When was the last downgrade for Disc Medicine (IRON)?
The last downgrade for Disc Medicine Inc happened on April 1, 2024 when Raymond James changed their price target from $75 to $40 for Disc Medicine Inc.
When is the next analyst rating going to be posted or updated for Disc Medicine (IRON)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Disc Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Disc Medicine was filed on March 2, 2026 so you should expect the next rating to be made available sometime around March 2, 2027.
Is the Analyst Rating Disc Medicine (IRON) correct?
While ratings are subjective and will change, the latest Disc Medicine (IRON) rating was a maintained with a price target of $78.00 to $79.00. The current price Disc Medicine (IRON) is trading at is $69.50, which is out of the analyst’s predicted range.
